INIS: AI 评分 48/100 — AI 分析 (4月 2026)

Radnostix, Inc. specializes in manufacturing and selling nuclear medicine calibration standards, cobalt-60 products, and radiopharmaceutical contract manufacturing services. The company operates across five segments, serving medical, industrial, and research applications in the United States and internationally.

Key Facts: AI Score: 48/100 Sector: Healthcare

公司概况

概要：

Radnostix, Inc. (INIS) focuses on niche nuclear medicine products and services, including calibration standards, cobalt-60, and radiochemicals. Operating in a specialized segment of the healthcare industry, the company caters to medical, industrial, and research sectors, facing competition from larger pharmaceutical and specialized manufacturers.

INIS是做什么的？

Radnostix, Inc., formerly International Isotopes Inc., was founded in 1995 and is headquartered in Idaho Falls, Idaho. The company manufactures and sells nuclear medicine calibration and reference standards, cobalt-60 products, and radiopharmaceutical and radiochemical contract manufacturing services, serving both domestic and international markets. Radnostix operates through five segments: Nuclear Medicine Standards, Cobalt Products, Radiochemical Products, Radiological Services, and Fluorine Products. The Nuclear Medicine Standards segment provides sources and standards for single photon emission computed tomography (SPECT) and positron emission tomography (PET) imaging, patient positioning, and dose measuring equipment calibration for the nuclear pharmacy industry. The Cobalt Products segment produces bulk cobalt, fabricates cobalt capsules for radiation therapy and industrial applications, and recycles expended cobalt sources. The Radiochemical Products segment produces and distributes isotopically pure radiochemicals and sodium iodide I-131 for medical, industrial, and research applications. The Radiological Services segment offers flood source disposal and gemstone processing services. The Fluorine Products segment focuses on producing small-scale qualification samples of high purity fluoride gas and developing processes for uranium de-conversion and fluorine extraction. Radnostix sells its products directly to end-users and distributors.

INIS的投资论点是什么？

Radnostix, Inc. presents a unique investment opportunity within the niche market of nuclear medicine and radiochemical products. With a market capitalization of $0.04 billion and a negative P/E ratio of -159.85, the company's financial performance necessitates careful evaluation. The gross margin of 44.2% indicates potential profitability in its specialized segments. Growth catalysts include the expansion of the Fluorine Products segment and increasing demand for radiochemicals. However, potential risks include the company's negative profit margin of -1.6% and the inherent challenges of operating in the OTC market. Investors should closely monitor the company's ability to achieve profitability and manage its operational costs. The beta of 1.28 suggests higher volatility compared to the broader market.

INIS在哪个行业运营？

Radnostix, Inc. operates within the specialty drug manufacturing industry, a segment characterized by high regulatory hurdles and specialized product offerings. The market for nuclear medicine and radiochemicals is driven by advancements in medical imaging and therapeutic applications. Competition includes both larger pharmaceutical companies and specialized manufacturers. Radnostix's focus on niche products like cobalt-60 and fluorine products allows it to carve out a specific market segment. The industry is subject to stringent regulations and requires significant investment in research and development.

Drug Manufacturers - Specialty & Generic

Healthcare

INIS有哪些增长机遇？

Expansion of Fluorine Products Segment: The Fluorine Products segment represents a significant growth opportunity for Radnostix, Inc. The segment is involved in the production of small-scale qualification samples of high purity fluoride gas for various industrial applications, as well as development of laboratory and analytical processes required to support the planned uranium de-conversion and fluorine extraction facility. Successful development and commercialization of these products could drive substantial revenue growth, potentially capturing a share of the industrial fluoride market.
Increased Demand for Radiochemical Products: The Radiochemical Products segment, which produces and distributes various isotopically pure radiochemicals and sodium iodide I-131 generic drug product for medical, industrial, and research applications, is poised for growth. Increasing demand for radiopharmaceuticals in diagnostic imaging and therapeutic applications, coupled with Radnostix's established production capabilities, presents a significant growth opportunity. Expanding the product portfolio and distribution network could further capitalize on this trend.
Strategic Partnerships and Acquisitions: Radnostix, Inc. could pursue strategic partnerships or acquisitions to expand its product offerings and market reach. Collaborating with other companies in the nuclear medicine or radiopharmaceutical space could provide access to new technologies, markets, and distribution channels. Acquiring complementary businesses could further diversify its product portfolio and enhance its competitive position. These initiatives could drive revenue growth and improve profitability.
Geographic Expansion: Radnostix, Inc. has the opportunity to expand its geographic presence beyond the United States. Entering new international markets, particularly in regions with growing healthcare infrastructure and demand for nuclear medicine products, could drive significant revenue growth. This expansion could involve establishing distribution partnerships, setting up local manufacturing facilities, or acquiring existing businesses in target markets.
Development of Novel Radiopharmaceuticals: Investing in the research and development of novel radiopharmaceuticals represents a long-term growth opportunity for Radnostix, Inc. Developing innovative diagnostic and therapeutic agents could create new revenue streams and enhance its competitive advantage. This could involve partnering with research institutions or universities to develop and commercialize new radiopharmaceutical products.

Market capitalization of $0.04 billion, reflecting its small-cap status within the healthcare sector.
Negative P/E ratio of -159.85, indicating current losses and the need for improved profitability.
Gross margin of 44.2%, showcasing the potential for profitability in its specialized product lines.
Beta of 1.28, suggesting higher volatility compared to the overall market.
Operates in five segments: Nuclear Medicine Standards, Cobalt Products, Radiochemical Products, Radiological Services, and Fluorine Products, providing diversification within the nuclear medicine market.

INIS提供哪些产品和服务？

Manufactures nuclear medicine calibration and reference standards.
Produces and sells cobalt-60 products for radiation therapy and industrial applications.
Provides radiopharmaceutical and radiochemical contract manufacturing services.
Offers isotopically pure radiochemicals and sodium iodide I-131 for medical, industrial, and research applications.
Provides flood source disposal and gemstone processing services.
Produces small-scale qualification samples of high purity fluoride gas.

INIS如何赚钱？

Manufacturing and selling nuclear medicine standards and cobalt-60 products.
Providing radiochemical and radiopharmaceutical contract manufacturing services.
Direct sales to end-users and distributors.
Revenue generation through five operating segments: Nuclear Medicine Standards, Cobalt Products, Radiochemical Products, Radiological Services, and Fluorine Products.

Nuclear pharmacies requiring calibration standards for imaging equipment.
Hospitals and clinics using cobalt-60 for radiation therapy.
Research institutions needing radiochemicals for experiments.
Industrial companies utilizing cobalt-60 for various applications.

Specialized product portfolio in nuclear medicine and radiochemicals.
Established manufacturing capabilities for cobalt-60 and radiopharmaceuticals.
Long-standing relationships with end-users and distributors.
Stringent regulatory requirements create barriers to entry for new competitors.

什么因素可能推动INIS股价上涨？

Ongoing: Expansion of the Fluorine Products segment, potentially leading to new revenue streams.
Ongoing: Increasing demand for radiochemical products in medical and industrial applications.
Upcoming: Potential strategic partnerships or acquisitions to expand product offerings and market reach.
Ongoing: Geographic expansion into new international markets.
Ongoing: Development of novel radiopharmaceuticals through research and development efforts.

INIS的主要风险是什么？

Ongoing: Stringent regulatory requirements and potential compliance costs.
Potential: Competition from larger pharmaceutical companies with greater resources.
Potential: Product liability risks associated with nuclear medicine products.
Potential: Fluctuations in raw material costs impacting profitability.
Ongoing: Negative P/E ratio indicating current losses and the need for improved profitability.

INIS的核心优势是什么？

Specialized product portfolio in nuclear medicine.
Established manufacturing capabilities.
Long-standing relationships with customers.
Diversified revenue streams across five segments.

INIS的劣势是什么？

Small market capitalization.
Negative P/E ratio indicating current losses.
Limited financial resources.
OTC market listing increases volatility.

INIS有哪些机遇？

Expansion of Fluorine Products segment.
Increased demand for radiochemical products.
Strategic partnerships and acquisitions.
Geographic expansion into new markets.

INIS面临哪些威胁？

Stringent regulatory requirements.
Competition from larger pharmaceutical companies.
Potential product liability risks.
Fluctuations in raw material costs.

INIS的竞争对手是谁？

D-Box Technologies Inc — Focuses on haptic technology, different market segment. — (DBCCF)
Dexterra Inc — Provides workforce management software, not direct competitor. — (DXBRF)
Earth Science Tech, Inc. — Focuses on nutraceuticals and cannabis, different market. — (ETST)
The Flowr Corporation — Cannabis company, not a direct competitor. — (FLOOF)
Medexus Pharmaceuticals Inc — Specialty pharmaceutical company, potential overlap in some therapeutic areas. — (MEDXF)

Key Metrics

MoonshotScore: 48/100

Company Profile

CEO: Shahe Bagerdjian
Headquarters: Idaho Falls, US
Employees: 41
Founded: 1997

AI Insight

AI analysis pending for INIS

OTC Tier: OTC Other
Disclosure Status: Unknown

常见问题

What does Radnostix, Inc. do?

Radnostix, Inc. manufactures and sells nuclear medicine calibration and reference standards, cobalt-60 products, and radiopharmaceutical and radiochemical contract manufacturing services. It operates through five segments: Nuclear Medicine Standards, Cobalt Products, Radiochemical Products, Radiological Services, and Fluorine Products. These products and services cater to medical, industrial, and research applications, serving both domestic and international markets. The company's focus on niche products within the nuclear medicine space differentiates it from larger pharmaceutical companies.

What do analysts say about INIS stock?

AI analysis is currently pending for INIS. Given its OTC listing and small market capitalization, analyst coverage may be limited. Investors should conduct their own thorough research and due diligence before making any investment decisions. Key valuation metrics to consider include the company's P/E ratio, gross margin, and revenue growth potential. The company's growth prospects are tied to the expansion of its Fluorine Products segment and increasing demand for radiochemical products.

What are the main risks for INIS?

The main risks for Radnostix, Inc. include its small market capitalization, negative P/E ratio, and OTC market listing. The company faces stringent regulatory requirements and competition from larger pharmaceutical companies. Product liability risks are inherent in the nuclear medicine industry. Fluctuations in raw material costs can impact profitability. The OTC listing increases volatility and reduces liquidity, making it riskier for investors. Limited financial disclosure adds to the uncertainty.

What revenue streams does Radnostix, Inc. have in healthcare?

Radnostix, Inc.'s revenue streams in healthcare are primarily derived from its Nuclear Medicine Standards and Radiochemical Products segments. The Nuclear Medicine Standards segment generates revenue from the sale of sources and standards associated with SPECT and PET imaging, patient positioning, and calibration of dose measuring equipment. The Radiochemical Products segment generates revenue from the production and distribution of isotopically pure radiochemicals and sodium iodide I-131 for medical applications. These revenue streams are driven by the demand for diagnostic imaging and therapeutic radiopharmaceuticals.

How does Radnostix, Inc. manage regulatory compliance in the nuclear medicine industry?

Radnostix, Inc. operates in a highly regulated industry and must adhere to stringent requirements set by regulatory bodies such as the Nuclear Regulatory Commission (NRC) and the Food and Drug Administration (FDA). The company invests in compliance programs, quality control measures, and safety protocols to ensure its products and services meet regulatory standards. Regular audits and inspections are conducted to verify compliance. Failure to comply with regulations could result in penalties, product recalls, and reputational damage.